Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.

Chin-Yao ShenPhilip Chun-Ming AuYeon-Hee BaekChing-Lung CheungWei-Pang ChungJu Hwan KimNora J KleinmanTai-Chung LamTzu-Chi LiaoTzu-Chieh LinJu-Young ShinChor-Wing SingIan Chi Kei WongEdward Chia-Cheng Lai

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2022)

Denosumab was associated with a lower risk of interruption than bisphosphonates in patients with bone metastases in Taiwan and Hong Kong. Further investigations may be required to verify patients' actual reasons for discontinuation.

Keyphrases

bone mineral density
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
drug delivery
bone loss